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ABSTRACT
Objective: This study aimed to determine the optimum concentrations of a suspending vehicle and develop a physically and chemically stable 
formulation containing diltiazem hydrochloride (DTZ).
Methods: Stability testing was performed for 30 days in selected suspending vehicle formulas (Formulas A and E). Physical stability tests were 
performed at room temperature, and physical properties (odor and color) and pH values of suspensions were evaluated.
Results: The oral suspensions of DTZ were white and had a drug-like odor, and the pH had significantly decreased during storage. Chemical stability 
tests of suspensions were performed at room temperature and 4°C±2°C using ultraviolet-visible spectrophotometry.
Conclusion: The concentrations of DTZ in oral suspensions fluctuated during the storage period, suggesting that the oral suspensions of DTZ are 
physically stable but not chemically stable during storage.
Keywords: Diltiazem hydrochloride, Suspending vehicle, Extemporaneous oral liquid formulation, Stability.
INTRODUCTION
Extemporaneous compounding in liquid vehicles facilitates the 
regulation of drug dosing in patients with swallowing difficulties 
and can provide greater ease for patients taking the drug [1]. 
Extemporaneous oral liquid compounding also has several advantages 
including masking of the bitter taste and uniformity of drug doses. In 
particular, extemporaneous oral liquid compounding will be of great 
use in pediatric patients [2,3].
Liquid oral formulation is comparatively quick to prepare and allow 
in the dosage form [4]. The lack of oral liquid drug formulations is 
problematic for patients with swallowing difficulties such as pediatric 
and geriatric patients. These patients require the production of 
extemporaneous compounding in liquid vehicles that are compatible 
with oral administration [5]. Accordingly, previous pharmaceutical 
studies show that formulations of extemporaneous compounding in 
liquid vehicles can assist patients with swallowing difficulty [6].
According to surveys conducted at several hospitals in Australia by 
Stewart and Tucker, 116 types of prescribed drugs were made into 
270 forms of extemporaneous compounding in liquid vehicles, and 
these are particularly used for pediatric patients. The preparation of 
extemporaneous compounding in liquid vehicles is relatively easy 
and can be achieved by simply dispersing the active drug agent into a 
suspending vehicle [2].
In Australia, Europe, and the United States, suspending vehicles for 
extemporaneous oral liquid compounding have been circulated in the 
market as Ora-Plus, which is a physically stable suspending vehicle with 
an elegant appearance and a uniform dose [6].
Herein, since the Ora-Plus vehicle is not available in Indonesia, we 
developed a suspending vehicle formulation for extemporaneous 
compounding using diltiazem hydrochloride (DTZ) as a drug model. 
This compound is a calcium channel blocker that is used for the 
treatment of angina pectoris and hypertension, particularly in 
pediatric and geriatric patients. It is highly protein bound 70–90% 
and undergoes extensive first-pass metabolism with relatively poor 
oral bioavailability of 40% [7]. We selected this drug as an active agent 
because it is compatible with suspending vehicles, which are intended 
for the treatment of pediatric and geriatric patients [8]. The present 
suspending vehicles were then evaluated for appearance, physical 
stability, and dose uniformity in combination with the active ingredient.
METHODS
Formulation of suspending vehicles
To produce suspending vehicles, suspending agents were dispersed in 
water and then stirred using a homogenizer. Preservative agents were 
then dissolved in solutions containing sufficient amounts of propylene 
glycol and were then added to suspending solutions. Mixtures were then 
homogenized using a homogenizer. Subsequently, buffer was dissolved 
in aquadest and was added to mixtures of suspending and preservative 
agents. After mixing using a homogenizer, dimethicone was added and 
mixed with the suspending agent, buffer, and preservative. Calcium 
sulfate was then dissolved in residual propylene glycol and was 
incorporated into the mixture using the homogenizer. Finally, sufficient 
volumes of aquadest were added quickly with stirring (Table 1).
Evaluations of suspending vehicles
Sedimentation volumes
Sedimentation volumes are ratios of the final volume of the sediment 
formed to the initial volume of the suspension vehicle before settling 
and are calculated using the following formula:
F (%)=100 Vu/Vo,
Where, F is the sedimentation volume, Vu is the final volume of sediment, 
and Vo is the initial volume of the suspension vehicle before settling.
To determine sedimentation volumes, 50-mL aliquots of the suspending 
vehicle were transferred to a measuring cup and sediment formation 
was monitored during storage for 1, 5, 10, 15, 20, 25, and 30 days [9].
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Redispersion
50 mL aliquots of suspending vehicle were placed into glass bottles 
and were stored at room temperature for 1 month. On days 1, 5, 10, 
15, 20, 25, and 30, redispersion tests were performed by shaking and 
observing redispersion of the sediments that formed during storage [9]. 
Comparisons were made in terms of numbers of shakes required to 
disperse sediments.
Viscosity tests
Viscosity was tested using a Brookfield viscometer at 100 rpm with 
spindles 1 or 2 depending on the viscosity of the suspending vehicle 
formulas [10]. Experiments were performed in triplicate and viscosities 
were expressed as means [9].
Particle size tests
Particle size testing was performed using a Mastersizer tool, which 
calculates particle size distributions in solutions of micron-sized particles. 
Experiments were performed 3 times and the data are expressed as mean 
particle size distributions for each suspending vehicle.
pH tests
Suspending vehicles were placed in glass beakers and pH values were 
measured using a pH meter that had been calibrated using buffer 
solutions at pH 4 and 7 [11].
Selection of suspending vehicle formulas
Active substance in the form of diluted DTZ tablets was incorporated 
into suspending vehicle formulas, and selected suspending vehicle 
formulas A and E were produced. Physical and chemical stability tests 
were conducted after 1 month, and DTZ levels in suspending vehicles 
were determined using ultraviolet (UV)-visible spectrophotometry.
To produce oral suspensions of DTZ, 24 tablets containing 30 mg of 
dilute DTZ were added to 60-mL aliquots of suspending vehicle to give a 
concentration of 12 mg/mL (Table 2). Mixtures were then shaken until 
DTZ powder was evenly dispersed in suspending vehicle. Sedimentation 
volume tests, redispersion tests, viscosity tests, pH tests, and physical 
and chemical stability tests were then performed at the indicated times.
Physical stability tests
Physical stability testing was performed at room temperature 
(25°C±2°C) with samples of selected suspending vehicle mixtures 
containing DTZ. Organoleptic observations (odor and color) were 
observed and pH values of vehicles were tested after 0, 3, 5, 10, 15, 20, 
25, and 30 days [1].
Determination of DTZ concentrations
Preparation of DTZ standard solution
Standard DTZ powder was weighed and 10-mg samples were added to 
100-mL measuring flasks. Subsequently, 50-mL aliquots of aquadest 
were added to the measuring flasks and were sonicated for 15 min. 
Flasks were then filled to volume with aquadest to achieve a standard 
concentration of 100-μg/mL DTZ, and 10-mL aliquots were then placed 
into 100 mL measuring flasks and were diluted 10-fold with aquadest 
to a final concentration of 10 μg/mL [12].
Determination of wavelength maxima
Wavelength maxima of the standard 10-μg/mL DTZ solution were 
determined using a UV-visible spectrophotometer at a wavelength 
range of 200–400 nm. Aquadest was used as the blank solution and a 
maximum wavelength of 236 nm was identified for the standard DTZ 
solution [12].
 DTZ calibration curve
Standard solutions containing 100-μg/mL DTZ were diluted into 
6-, 8-, 10-, 12-, 14-, and 16-μg/mL solutions. Absorbance was then 
determined using a UV-visible spectrophotometer at 236 nm. The 
relationship between absorbance and concentration was expressed as a 
linear regression equation and is presented as a calibration curve [12].
Determination of DTZ tablet concentrations
A total of 20 tablets containing 30 mg of DTZ each were weighed 
and then powdered, and average weights were then calculated. An 
equivalent powder containing 10 mg of DTZ was dissolved in 30 mL of 
aquadest using sonication and was then diluted to volume in 100 mL of 
aquadest. Subsequently, 5-mL aliquots of the first filtrates were removed 
and diluted to 10 μg/mL, and DTZ concentrations were determined in 
triplicate at 236 nm using a UV-visible spectrophotometer [12].
Determination of DTZ concentrations in suspensions
Suspensions of 5 mL containing 60 mg of DTZ were extracted in a 
separating funnel using 50 mL of chloroform. Mixtures were shaken 
for about 1 min and after separation from suspension phases, organic 
phases were taken and filtered through Whatman filter paper No. 42. 
Filtrates were then dried in a vaporizer plate in an acid cupboard until 
the chloroform had evaporated entirely. The resulting residues were 
then added to 50-mL measuring flasks and were diluted to volume 
in aquadest. Further, dilutions were performed with 1-mL aliquots 
of solution in 100-mL measuring flasks to achieve a concentration of 
1 μg/mL. DTZ concentrations were then determined at a wavelength of 
238.4 nm using a UV-visible spectrophotometer in triplicate [13].
Table 1: Suspending vehicle formulations
Material components Formula (%)
A B C D E F G
Microcrystalline cellulose 0.5 3 3 3 - - -
Sodium carboxymethylcellulose 0.5 0.5 - - 0.5 0.5 -
Xanthan gum 0.1 - 0.1 - 0.1 - 0.1
Carrageenan 0.5 - - 0.75 - 0.75 0.75
Calcium sulfate 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Methylparaben 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Potassium sorbate 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Citric acid 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Sodium dihydrogen phosphate 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Dimethicone 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Propylene glycol 10 10 10 10 10 10 10
Aquadest ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ad 100
Table 2: DTZ contents in suspending vehicle
Material components Total Final concentration
DTZ tablet 30 mg 24 tablet 12 mg/mL
Selected suspending vehicle Add 60 mL
DTZ: Diltiazem hydrochloride
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Chemical stability test
Selected suspending vehicles containing DTZ tablets were stored at 
4°C±2°C and at room temperature 25°C±2°C for 1 month [1].
RESULTS AND DISCUSSION
Suspending vehicle formula
Microcrystalline cellulose, sodium carboxymethylcellulose, xanthan 
gum, and carrageenan were selected as suspending agents because 
the Ora-Plus vehicle contains these four suspending agents. For 
comparisons, formulations were prepared using two variations of 
suspending materials. Other ingredients that are used as additives 
in the formulation of suspending vehicles include calcium sulfate 
as a flocculating agent, methylparaben and potassium sorbate as 
preservatives, citric acid and sodium dihydrogen phosphate as buffers, 
dimethicone as an antifoaming agent, propylene glycol as stabilizing 
agent, and aquadest as a solvent.
Evaluations of suspending vehicle
Sedimentation volumes
Observations of sedimentation volumes in the present seven suspending 
vehicle formulations were performed after storage for 1, 5, 10, 15, 20, 
25, and 30 days (Table 3).
The sedimentation volume of formula A indicated optimal vehicle 
characteristics, with no sedimentation at any of the observation times. 
These properties are in accordance with those of good suspensions, 
particularly because the particles in the vehicle were homogenously 
suspended and did not sediment quickly. Sedimentation rates are 
inversely proportional to vehicle viscosities. Thus, greater viscosity 
prevents the formations of sediments from suspension, as indicated 
by the lower sedimentation volumes seen in experiments with 
formula A.
The sedimentation volume in formula C was low at 14%, although this 
value may in part reflect the density of the formed sediment. Likewise, 
formula B had a low sedimentation volume at 22%, and similar to 
formula C formed compact and hard caked sediments after prolonged 
storage. Although these sedimentation volumes were small, they were 
unfavorably difficult to disperse, indicating physical instability of the 
suspensions.
Formula E had the second lowest sedimentation value after 
formula C, and after addition of DTZ tablets, weak interactions with 
suspending agents allowed rapid sedimentation. In contrast with the 
aforementioned formulas that form hard cake sediments, sediments 
from formula E tended to be stable for short times and were easier to 
resuspend with shaking. Hence, given the sedimentation volume after 
the addition of DTZ, the best formulation was formula E.
Redispersion
During storage, the suspending vehicle precipitates and the formed 
sediment must be redispersed by shaking to ensure appropriate doses 
at delivery. Thus, we compared redispersion of suspending vehicle 
formulas to rectify the sedimented particle so that with shaking, the 
particles in the vehicle can be evenly dispersed again [9].
In comparisons of the seven formulas, those for which formed sediments 
could be dispersed by shaking were favored because they did not form 
caked sediments after 30 days of storage. Formula A was the easiest 
formula to regenerate because it formed less sediment than the other 
formulas. Formula A also had favorable redispersion characteristics 
of the vehicle. In contrast, formula B required the most agitation to 
disperse the sediment evenly, and the sediment formed hard cakes 
after longer storage periods. Redispersion of formulas was compared in 
terms of numbers of shakes required (Table 4).
Viscosity tests
Viscosity tests were performed on the seven suspending vehicle formulas 
with and without DTZ tablets. In these experiments, formula A had the 
greatest viscosity, reflecting its four suspending agents. In formula C, high 
viscosity was observed due to the combination of cellulose microcrystalline 
and xanthan gum, and the latter is known to have a high viscosity degree 
at low concentrations. Compared with formula E, which also comprises 
a mixture of xanthan gum and sodium carboxymethylcellulose, the 
viscosity of formula C was higher. These observations can be explained by 
the presence of cellulose microcrystalline at 3% in formula C, compared 
with carboxymethylcellulose sodium at only 0.5% in formula E. 
Furthermore, the viscosity produced by sodium carboxymethylcellulose 
in solutions was higher than that of carrageenan, reflecting the ease of 
expansion of the former following dispersion in hot water. Therefore, 
dispersion of sodium carboxymethylcellulose in hot water may be causal 
of the high viscosity of formulas B and F. When compared with formula B, 
however, formula F had lower viscosity than B formula, which contained 
3% microcrystalline cellulose, whereas formula F only contained 
carrageenan at 0.75%. Formula D had higher viscosity than formula G, 
despite having equal carrageenan contents. This can be explained by 
the presence of higher cellulosic microcrystalline contents in formula 
D then gum xanthan concentrations in formula G. Thus, in decreasing 
order of viscosity, the formulas are arranged as follows: C, E, B, F, D, and G 
(Table 5).
Particle sizes
D values (4.3) were calculated to indicate average particle sizes of 
formulations. Of the seven suspending vehicle formulas, formula E had the 
largest particle size, with a D value (4.3) of 234 μm reflecting the mixture 
of sodium carboxymethylcellulose and xanthan gum (Fig. 1). Both of these 
suspending agents have high degrees of pseudoplasticity and form clear 
colloidal solutions when dispersed in water. Furthermore, in the formula G, 
which was a mixture of xanthan gum and carrageenan, the resulting 
particle size was larger than that of formula C, which comprises a mixture 
of xanthan gum and microcrystalline cellulose. Xanthan gum also has a 
high degree of pseudoplasticity, but in comparisons of formulas G and C, 
particle sizes were greater in G because the carrageenan was dispersed 
in warm water to form hydrocolloids. In contrast, dispersion of cellulosic 
microcrystalline in water results in comparatively dilute solutions. Formula 
D comprised a mixture of cellulose microcrystalline and carrageenan and 
had the smallest particle size, with a D value (4.3) of 41.9 μm.
pH tests
In pH tests of the vehicle, pH values decreased after addition of DTZ 
tablets to all seven suspending vehicle formulas (Fig. 2). These 




Formula A Formula B Formula C Formula D Formula E Formula F Formula G
1 0 22 10 70 22 0 0
5 0 22 14 66 22 0 96
10 0 22 14 64 20 0 94
15 0 22 14 64 20 96 92
20 0 22 14 64 20 96 86
25 0 22 14 64 20 94 80
30 0 22 14 64 20 92 76
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Formula A Formula B Formula C Formula D Formula E Formula F Formula G
1 1 6 6 3 4 2 1
5 1 15 11 4 5 2 2
10 1 16 12 4 7 2 2
15 1 16 12 4 7 2 2
20 1 16 12 4 7 2 2
25 1 16 12 4 7 2 2
30 1 16 12 4 7 2 2
Table 5: Mean viscosities of formulas A–G
Viscosity Formula
A B C D E F G
Mean value suspending vehicle (cPs) 586.67 116.67 125 88 114.67 97.33 61.33
Mean value DTZ suspension (cPs) 130.67 101.67 123 96 114.67 97.33 101.33
DTZ: Diltiazem hydrochloride
Fig. 1: Particle size distributions of formulas A–G
Fig. 2: Graph of pH ratios between suspending vehicle and suspension after addition of diltiazem hydrochloride tablets
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decreases in pH are due to the acidity of DTZ tablets, which produced 
pH values of 4.3–5.3 in suspending vehicles [14].
Physical stability tests
Color and odor observations of formulas A and E showed no changes 
from day 0 to day 30 of storage (Table 6). Formula A was white and had a 
distinctive odor, and E formula was similarly white and had a similar drug 
odor. The absence of changes during storage suggests that formulas A and E 
remain stable at room temperature, even after the addition of DTZ tablets.
Decreasing pH values in formulas A and E during storage may be due 
to hydrolysis processes in suspensions. In particular, carrageenan is 
susceptible to hydrolysis and in water is hydrolyzed by acid, leading to 
further pH decreases.
Physical stability tests of the drug agent showed no changes during 
decreases in pH of formulas A and E at room temperature, indicating 
stability of the agent.
Determination of drug concentrations
Determination of DTZ tablet concentrations
DTZ tablet concentrations were determined using UV-visible 
spectrophotometry at the wavelength maxima of 236.0 nm and 
10 ppm [13]. From concentrations of 6.18, 8.24, 10.3, 12.36, 14.42, and 
16.48 ppm, the standard curve was described by the linear regression 
equation y=0.0444x+0.0132 (r=0.9989).
Using this standard curve for DTZ, DTZ contents of 30 mg tablets were 
determined in triplicate, revealing 99.279%, 101.306%, and 103.333% 
of the 30-mg added.
Determination of DTZ concentrations in suspensions
DTZ concentrations were determined in suspensions using UV-visible 
spectrophotometry. Samples of suspending vehicle containing 30-mg 
DTZ tablets were analyzed after 0, 10, 20, and 30 days of storage at 
room temperature (25°C±2°C) and in a refrigerator (4°C±2°C).
Absorption spectra of DTZ differed between the 1st and past days 
of storage, particularly in formulations formula A and E at room 
temperature and in the refrigerator (Table 7). These data indicate that 
determinations of drug contents are not quantitative and suggest that 
the long extraction process using chloroform, which was performed 
with 24 h evaporation, introduces other compounds that can absorb 
at the same maximum wavelength, thus influencing determinations at 
the time of analysis. In addition, differences in the assay results may 
reflect a temporary diffusion process between the suspension and the 
organic chloroform phase during shaking for 1 min. This may decrease 
concentrations of active substance, with active ingredient remaining 
in the chloroform fraction. Nonetheless, chloroform is required to 
separate active ingredient from suspensions for the determinations of 
concentrations of DTZ in suspensions.
CONCLUSION
The present physical stability test results show that our suspension 
carrier is physically stable for 30 days storage at room temperature, 
but that DTZ formulations were chemically unstable. In comparisons 
of the present formulations, the best suspending oral vehicle for DTZ 
was formula A.
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Table 7: Determinations of DTZ concentrations in suspensions
Condition Formula Days Concentration 
(mean) (%)
Room temperature Formula A 0 75.11±8.426
10 91.99±2.817
20 84.11±0.964





Room temperature Formula E 0 83.54±1.315
10 78.85±6.848
20 62.21±5.066






Table 6: Physical stability tests of Formulas A and E
Days pH
Formula A Formula E
0 3.83 3.86
3 3.78 3.68
5 3.70 3.61
10 3.62 3.60
15 3.61 3.59
20 3.58 3.57
25 3.56 3.46
30 3.50 3.47
